Kiora Pharmaceuticals (KPRX) Cash & Current Investments (2016 - 2025)
Kiora Pharmaceuticals (KPRX) has disclosed Cash & Current Investments for 11 consecutive years, with $1.0 million as the latest value for Q2 2025.
- For the quarter ending Q2 2025, Cash & Current Investments fell 84.8% year-over-year to $1.0 million, compared with a TTM value of $1.0 million through Jun 2025, down 84.8%, and an annual FY2024 reading of $26.8 million, up 989.57% over the prior year.
- Cash & Current Investments was $1.0 million for Q2 2025 at Kiora Pharmaceuticals, down from $20.3 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $31.3 million in Q1 2024 and bottomed at $1.0 million in Q2 2025.
- Average Cash & Current Investments over 5 years is $10.4 million, with a median of $6.6 million recorded in 2024.
- The sharpest move saw Cash & Current Investments surged 989.57% in 2024, then tumbled 84.8% in 2025.
- Year by year, Cash & Current Investments stood at $7.9 million in 2021, then crashed by 38.6% to $4.9 million in 2022, then plummeted by 49.31% to $2.5 million in 2023, then soared by 989.57% to $26.8 million in 2024, then tumbled by 96.27% to $1.0 million in 2025.
- Business Quant data shows Cash & Current Investments for KPRX at $1.0 million in Q2 2025, $20.3 million in Q1 2025, and $26.8 million in Q4 2024.